3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
4
Gynecologic
2
Tumor-Agnostic
1
Thoracic
1
Head & Neck
1
Genitourinary
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Adenocarcinoma of Lung
1
Interventions
Paclitaxel
161
Fulvestrant
155
Trastuzumab
152
pembrolizumab
144
Letrozole
136
Carboplatin
118
pertuzumab
104
Cyclophosphamide
102
Capecitabine
102
Specimen Handling
101
Anastrozole
90
palbociclib
85
abemaciclib
81
Magnetic Resonance Spectroscopy
81
exemestane
76
Docetaxel
76
Tamoxifen
75
ribociclib
73
trastuzumab deruxtecan
69
Radiotherapy
61
Biopsy
59
Surveys and Questionnaires
56
Gemcitabine
52
130-nm albumin-bound paclitaxel
52
sacituzumab govitecan
50
olaparib
50
Standard of Care
49
Blood Specimen Collection
49
Taxes
47
Doxorubicin
47
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
bemarituzumab
×
Breast
×
1 year
×
Clear all
NCT05325866
2026-02-04
FORTITUDE-301
Amgen
Phase 1/2
Completed
260 enrolled